Concanamycin B

Concanamycin B

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Concanamycin B
Category Antibiotics
Catalog number BBF-01734
CAS 81552-33-2
Molecular Weight 852.06
Molecular Formula C45H73NO14
Purity >95% by HPLC

Online Inquiry

Description

It is produced by the strain of Streptomyces diastatochromogenes. It has antifungal, antiviral, immunosuppressive, cytotoxic and other activities, and is a specific inhibitor of V-type ATPase, which is an important tool for biochemical research.

Specification

Synonyms (3Z,5E,7R,8R,9S,10S,11R,13E,15E,17S,18R)-18-[(1S,2R,3S)-3-[(2R,4R,5S,6R)-4-[[4-O-(Aminocarbonyl)-2,6-dideoxy-β-D-arabino-hexopyranosyl]oxy]tetrahydro-2-hydroxy-5-methyl-6-(1E)-1-propenyl-2H-pyran-2-yl]-2-hydroxy-1-methylbutyl]-8,10-dihydroxy-3,17-dimethoxy-5,7,9,11,13-pentamethyloxacyclooctadeca-3,5,13,15-tetraen-2-one; MCH 210; 8-Deethyl-8-methylconcanamycin A
Storage -20 °C
IUPAC Name [(2R,3S,4R,6R)-6-[(2R,4R,5S,6R)-2-[(2S,3R,4S)-4-[(2R,3S,4E,6E,9R,10S,11S,12R,13R,14E,16Z)-10,12-dihydroxy-3,17-dimethoxy-7,9,11,13,15-pentamethyl-18-oxo-1-oxacyclooctadeca-4,6,14,16-tetraen-2-yl]-3-hydroxypentan-2-yl]-2-hydroxy-5-methyl-6-[(E)-prop-1-enyl]oxan-4-yl]oxy-4-hydroxy-2-methyloxan-3-yl] carbamate
Canonical SMILES CC=CC1C(C(CC(O1)(C(C)C(C(C)C2C(C=CC=C(CC(C(C(C(C(C=C(C=C(C(=O)O2)OC)C)C)O)C)O)C)C)OC)O)O)OC3CC(C(C(O3)C)OC(=O)N)O)C
InChI InChI=1S/C45H73NO14/c1-13-15-33-27(6)36(57-37-21-32(47)42(31(10)56-37)59-44(46)52)22-45(53,60-33)30(9)40(50)29(8)41-34(54-11)17-14-16-23(2)18-25(4)38(48)28(7)39(49)26(5)19-24(3)20-35(55-12)43(51)58-41/h13-17,19-20,25-34,36-42,47-50,53H,18,21-22H2,1-12H3,(H2,46,52)/b15-13+,17-14+,23-16+,24-19+,35-20-/t25-,26-,27-,28+,29+,30+,31-,32-,33-,34+,36-,37+,38+,39-,40-,41-,42-,45-/m1/s1
InChI Key AQXXGIBOZQZSAT-XDUMZDCNSA-N
Source Streptomyces sp.

Properties

Appearance Crystal
Antibiotic Activity Spectrum Fungi; Viruses
Boiling Point 960.2 °C at 760 mmHg
Density 1.20 g/cm3
Solubility Soluble in Isopropyl Alcohol, Methanol, Chloroform, DMF, DMSO; Poorly soluble in Water

Reference Reading

1. Involvement of the vacuolar H(+)-ATPases in the secretory pathway of HepG2 cells
A Tan, H L Ploegh, K Ito, M Yilla, K Miwa J Biol Chem . 1993 Sep 5;268(25):19092-100.
The macrolide antibiotic concanamycin B is a highly selective inhibitor (IC50 = 5 nM) of the H(+)-ATPases of the vacuolar system. We have examined the effects of concanamycin B on the constitutive secretory pathway of the human hepatoma cell line, HepG2. In cells exposed to 10 nM concanamycin B, transport from the endoplasmic reticulum to the Golgi occurs at normal rates, as determined by pulse-chase analysis of endoglycosidase H-sensitive product in conjunction with subcellular fractionation experiments. However, intra-Golgi trafficking or Golgi to plasma membrane delivery is significantly impaired. A delay in the onset of secretion of the major secretory proteins, albumin, alpha 1-antitrypsin and transferrin is observed. Processing of N-linked glycans by sialyltransferases is inhibited, resulting in secreted glycoproteins which are modified less extensively. In view of the acidic pH of the trans-Golgi and the trans-Golgi network, these studies suggest that acidification by vacuolar ATPases is critical to achieving timely secretion and correct N-linked glycan modifications of proteins which follow the constitutive secretory pathway.
2. Inhibition of the acidification of endosomes and lysosomes by the antibiotic concanamycin B in macrophage J774
K Sakai, C Shinohara, A Endo, J T Woo, K Hasumi Eur J Biochem . 1992 Jul 1;207(1):383-9. doi: 10.1111/j.1432-1033.1992.tb17061.x.
The antibiotic concanamycin B was found to inhibit oxidized-low-density-lipoprotein(LDL)-induced accumulation of lipid droplets in the macrophage J774 at a concentration of 5-10 nM. Concanamycin B inhibited cholesteryl-ester synthesis from [14C]oleate by 50% at 14 nM without affecting the synthesis of triacylglycerol and polar lipids. Degradation of internalized oxidized 125I-LDL was inhibited by about 80% in cells treated with 25 nM concanamycin B, while cell-surface binding of oxidized 125I-LDL at 4 degrees C, uptake of surface-bound oxidized 125I-LDL and microsomal acyl-CoA:cholesterol acyltransferase activity were not significantly affected by the antibiotic at 25 nM. When J774 cells were treated with 25 nM concanamycin B at 37 degrees C for 60 min, there was a reduction of about 50% in the activity of cell-surface receptors. This reduction appeared to be due to partial trapping of the receptors within the cells. Concanamycin B significantly inhibited ATP-dependent acidification of endosomes and lysosomes of the J774 cells at a concentration of 4 nM. Since acidic condition of these organelles is required for receptor recycling and hydrolysis of lipoproteins, the results demonstrate that concanamycin-B inhibition of oxidized-LDL-induced accumulation of lipid droplets and cholesteryl esters in macrophages J774 is associated with reduced ATP-dependent acidification of these organelles.
3. Concanamycin B, a vacuolar H(+)-ATPase specific inhibitor suppresses bone resorption in vitro
K Tagami, K Sumitani, K Yamaguchi, J T Woo, T Tsuji, Y Ohba Biol Pharm Bull . 1996 Feb;19(2):297-9. doi: 10.1248/bpb.19.297.
Effects of concanamycin B, a specific inhibitor of the vacuolar type H(+)-ATPase (V-ATPase), on the stimulation of bone resorption induced by parathyroid hormone (PTH) were examined in vitro. Concanamycin B was found to inhibit PTH-stimulated osteoclastic pit formation and to suppress the acidification of vacuolar organelles by V-ATPase in the osteoclasts. PTH-stimulated 45Ca release from prelabelled chick embryonic calvariae was also inhibited by concanamycin B in a dose-dependent manner. These results suggest that osteoclastic acidification of lacunae by V-ATPase plays an essential role in mineral dissolution and degradation of the organic matrix during bone resorption.

Recommended Products

Bio Calculators

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g

Recently viewed products

Online Inquiry

Verification code
cartIcon
Inquiry Basket